Stay updated on Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial page.

Latest updates to the Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial page
- Check5 days agoChange DetectedSite revision update from v3.3.1 to v3.3.2 with no changes to the study details or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check13 days agoChange DetectedRevision updates detected: added Revision: v3.3.1 and removed Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check20 days agoChange DetectedRemoved the government funding lapse notice regarding potential delays in updates; the page now omits that disclaimer.SummaryDifference0.1%

- Check34 days agoChange DetectedNo substantive changes detected; observed updates appear limited to minor UI text tweaks and the page's last updated timestamp, with core study content, eligibility criteria, primary outcomes, and locations remaining the same. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference1%

- Check70 days agoChange DetectedThe page shifts from detailed cancer histology terms to broader immunology-related topics and updates to a new revision (v3.1.0), removing several cancer-specific classifications (v3.0.2).SummaryDifference2%

Stay in the know with updates to Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial page.